04.08.14
Icon plc, a Dublin, Ireland-based provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, will acquire Aptiv Solutions for $143.5 million in cash.
Reston,Va.-based Aptiv Solutions—which is owned by the Halifax Group, SV Life Sciences, Comvest Partners and management—helps pharmaceutical and biotech clients using its model for adaptive clinical trials. Aptiv has operations in 16 countries, and includes Niphix, a full-service, oncology-focused clinical research organization serving Japanese and international customers, which will be combined with Icon’s current Japanese operations in Tokyo and Osaka. Aptiv Solutions also has experience managing medical device trials.
“Icon’s innovation is helping our customers reduce the time and cost of drug development,” said Dr. Nuala Murphy, president of Icon Clinical Research Services. “We are achieving this through our expertise and enabling technologies such as Iconik and Firecrest. Aptiv Solutions’ adaptive trial capabilities will further differentiate and enhance our services to help customers identify the most promising drug candidates earlier. Their presence in Japan will also broaden our existing capabilities in this market.”
“Icon is the perfect fit for Aptiv Solutions,” said Pat Donnelly, chairman and CEO of Aptiv Solutions. “Our technology and expertise in integrated design and execution of adaptive trials, our strength in medical device development and our strong position in oncology in Japan are key areas of differentiation. Icon’s excellence in execution, geographic reach, and shared focus on innovation will position the combined entity as the go-to service provider for design and execution of adaptive trials for drug, diagnostic and medical device companies in a fast-growing market.”
Icon specializes in the strategic development, management and analysis of programs that support clinical development, from compound selection to Phase I-IV clinical studies. The company has roughly 10,300 employees, operating from 77 locations in 38 countries.
Reston,Va.-based Aptiv Solutions—which is owned by the Halifax Group, SV Life Sciences, Comvest Partners and management—helps pharmaceutical and biotech clients using its model for adaptive clinical trials. Aptiv has operations in 16 countries, and includes Niphix, a full-service, oncology-focused clinical research organization serving Japanese and international customers, which will be combined with Icon’s current Japanese operations in Tokyo and Osaka. Aptiv Solutions also has experience managing medical device trials.
“Icon’s innovation is helping our customers reduce the time and cost of drug development,” said Dr. Nuala Murphy, president of Icon Clinical Research Services. “We are achieving this through our expertise and enabling technologies such as Iconik and Firecrest. Aptiv Solutions’ adaptive trial capabilities will further differentiate and enhance our services to help customers identify the most promising drug candidates earlier. Their presence in Japan will also broaden our existing capabilities in this market.”
“Icon is the perfect fit for Aptiv Solutions,” said Pat Donnelly, chairman and CEO of Aptiv Solutions. “Our technology and expertise in integrated design and execution of adaptive trials, our strength in medical device development and our strong position in oncology in Japan are key areas of differentiation. Icon’s excellence in execution, geographic reach, and shared focus on innovation will position the combined entity as the go-to service provider for design and execution of adaptive trials for drug, diagnostic and medical device companies in a fast-growing market.”
Icon specializes in the strategic development, management and analysis of programs that support clinical development, from compound selection to Phase I-IV clinical studies. The company has roughly 10,300 employees, operating from 77 locations in 38 countries.